biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB
Solid Biosciences
Solid Biosciences clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
- Founded
- 2013
- Employees
- 155
- Programs
- 16
- Drugs
- 20
- Patents
- 2
Solid Biosciences projects
7 ClinicalTrials.gov programs sponsored by Solid Biosciences.
Solid Biosciences has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CWS-2007-HR
Solid Biosciences
Soft Tissue Sarcoma
1 trial -
IP
Solid Biosciences
Small Cell Lung Cancer
1 trial -
SGT-003
Solid Biosciences
Duchenne Muscular Dystrophy
2 trials -
dactinomycin
Solid Biosciences
Sarcoma
1 trial -
filgrastim
Solid Biosciences
Ovarian Cancer
1 trial -
filgrastim
Solid Biosciences
Lung Cancer
1 trial -
filgrastim
Solid Biosciences
Lymphoma
2 trials
Frequently asked questions
How many clinical projects does Solid Biosciences have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.